Perez-Belmonte, Luis MSanz-Canovas, JaimeGarcia-de-Lucas, Maria DRicci, MicheleAviles-Bueno, BeatrizCobos-Palacios, LidiaPerez-Velasco, Miguel ALopez-Sampalo, AlmudenaBernal-Lopez, M RosaJansen-Chaparro, SergioMiramontes-Gonzalez, Jose PGomez-Huelgas, Ricardo2023-05-032023-05-032022-06-24Pérez-Belmonte LM, Sanz-Cánovas J, García de Lucas MD, Ricci M, Avilés-Bueno B, Cobos-Palacios L, et al. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Front Endocrinol (Lausanne). 2022 Jun 24;13:8510351664-2392http://hdl.handle.net/10668/20560The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Health statusHeart failureObesitySemaglutideType 2 diabetesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesHeart FailureHumansObesityRetrospective Studiesresearch article35813629open accessInsuficiencia CardíacaDiabetes Mellitus Tipo 2Agonistas Receptor de Péptidos Similares al GlucagónObesidadCardiomiopatíasEstado Funcional10.3389/fendo.2022.851035PMC9263111https://www.frontiersin.org/articles/10.3389/fendo.2022.851035/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263111/pdf